DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy.

[1]  J. Champoux,et al.  The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. , 2006, Journal of molecular biology.

[2]  G. H. Coombs,et al.  Leishmania donovani: differential activities of classical topoisomerase inhibitors and antileishmanials against parasite and host cells at the level of DNA topoisomerase I and in cytotoxicity assays. , 2006, Experimental parasitology.

[3]  E. Ashley,et al.  Artemisinin-based combinations , 2005, Current opinion in infectious diseases.

[4]  Heather J Munden,et al.  The Genome of the Kinetoplastid Parasite, Leishmania major , 2005, Science.

[5]  Daniel Nilsson,et al.  Comparative Genomics of Trypanosomatid Parasitic Protozoa , 2005, Science.

[6]  B. Haas,et al.  The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease , 2005, Science.

[7]  David M. A. Martin,et al.  The Genome of the African Trypanosome Trypanosoma brucei , 2005, Science.

[8]  D. González-Pacanowska,et al.  Overexpression of AP endonuclease protects Leishmania major cells against methotrexate induced DNA fragmentation and hydrogen peroxide. , 2005, Molecular and biochemical parasitology.

[9]  P. Yogeeswari,et al.  Camptothecin and its analogues: a review on their chemotherapeutic potential , 2005, Natural product research.

[10]  N. Sen,et al.  N-terminal Region of the Large Subunit of Leishmania donovani Bisubunit Topoisomerase I Is Involved in DNA Relaxation and Interaction with the Smaller Subunit* , 2005, Journal of Biological Chemistry.

[11]  M. Olivier,et al.  Topoisomerase I Amino Acid Substitutions, Gly185Arg and Asp325Glu, Confer Camptothecin Resistance in Leishmania donovani , 2005, Antimicrobial Agents and Chemotherapy.

[12]  D. Steverding,et al.  Anti-trypanosomal activities of DNA topoisomerase inhibitors. , 2005, Acta tropica.

[13]  G. Harms,et al.  The impact of HIV infection on tropical diseases. , 2005, Infectious disease clinics of North America.

[14]  Y. Pommier,et al.  Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. , 2005, Journal of medicinal chemistry.

[15]  Y. Pommier,et al.  Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison , 2005, Molecular Pharmacology.

[16]  David J Adams,et al.  The impact of tumor physiology on camptothecin-based drug development. , 2005, Current medicinal chemistry. Anti-cancer agents.

[17]  N. Sen,et al.  Camptothecin-induced Imbalance in Intracellular Cation Homeostasis Regulates Programmed Cell Death in Unicellular Hemoflagellate Leishmania donovani* , 2004, Journal of Biological Chemistry.

[18]  N. Saravia,et al.  INHIBITION OF LEISHMANIA DONOVANI PROMASTIGOTE DNA TOPOISOMERASE I AND HUMAN MONOCYTE DNA TOPOISOMERASES I AND II BY ANTIMONIAL DRUGS AND CLASSICAL ANTITOPOISOMERASE AGENTS , 2004, The Journal of parasitology.

[19]  P. Desjeux.  Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[20]  J. Shlomai.  The structure and replication of kinetoplast DNA. , 2004, Current molecular medicine.

[21]  Yves Pommier,et al.  Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. , 2004, Current medicinal chemistry. Anti-cancer agents.

[22]  A. Dasgupta,et al.  Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. , 2004, Trends in parasitology.

[23]  T. Shapiro,et al.  RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. , 2004, Molecular and biochemical parasitology.

[24]  N. Sen,et al.  Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani , 2004, Cell Death and Differentiation.

[25]  J. Alvar,et al.  Virulence and disease in leishmaniasis: what is relevant for the patient? , 2004, Trends in parasitology.

[26]  G. Capranico,et al.  Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges. , 2004, Current medicinal chemistry. Anti-cancer agents.

[27]  J. Cannata,et al.  Purification and properties of poly(ADP-ribose)polymerase from Crithidia fasciculata. Automodification and poly(ADP-ribosyl)ation of DNA topoisomerase I. , 2004, Molecular and biochemical parasitology.

[28]  J. Berger,et al.  Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. , 2004, Annual review of biophysics and biomolecular structure.

[29]  N. Sen,et al.  Reconstitution and functional characterization of the unusual bi‐subunit type I DNA topoisomerase from Leishmania donovani , 2004, FEBS letters.

[30]  J. Jannin,et al.  Human African trypanosomiasis. , 2004 .

[31]  J. Jannin,et al.  Focus: Human African trypanosomiasis , 2004, Nature Reviews Microbiology.

[32]  Nico P E Vermeulen,et al.  Enzyme-Catalyzed Activation of Anticancer Prodrugs , 2004, Pharmacological Reviews.

[33]  P. Kennedy,et al.  Human African trypanosomiasis of the CNS: current issues and challenges. , 2004, The Journal of clinical investigation.

[34]  H. Sindermann,et al.  [Leishmaniasis--oral treatment with hexadecylphosphocholine]. , 2004, Wiener klinische Wochenschrift.

[35]  K. Kohn,et al.  Repair of and checkpoint response to topoisomerase I-mediated DNA damage. , 2003, Mutation research.

[36]  J. Urbina,et al.  Specific chemotherapy of Chagas disease: controversies and advances. , 2003, Trends in parasitology.

[37]  S. Croft,et al.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. , 2003, Trends in parasitology.

[38]  J. May,et al.  Chemoresistance in falciparum malaria. , 2003, Trends in parasitology.

[39]  E. LaVoie,et al.  EFFECTS OF TOPOISOMERASES INHIBITORS PROTOBERBERINE ON LEISHMANIA DONOVANI GROWTH, MACROPHAGE FUNCTION, AND INFECTION , 2003, The Journal of parasitology.

[40]  T. Shapiro,et al.  DNA topoisomerases as targets for antiprotozoal therapy. , 2003, Mini reviews in medicinal chemistry.

[41]  M. Miles,et al.  American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies , 2003, BMJ : British Medical Journal.

[42]  A. Bodley,et al.  An unusual type IB topoisomerase from African trypanosomes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Le bras,et al.  The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum , 2003, Fundamental & clinical pharmacology.

[44]  P. Myler,et al.  A Novel Active DNA Topoisomerase I in Leishmania donovani * , 2003, The Journal of Biological Chemistry.

[45]  B. Friguet,et al.  Characterization and role of protozoan parasite proteasomes. , 2003, Trends in parasitology.

[46]  Y. Pommier,et al.  Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.

[47]  A. Goswami,et al.  Dihydrobetulinic Acid Induces Apoptosis in Leishmania donovani by Targeting DNA Topoisomerase I and II: Implications in Antileishmanial Therapy , 2003, Molecular medicine.

[48]  Y. Taketani,et al.  SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin , 2002, Oncogene.

[49]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Jonathan E. Allen,et al.  Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii , 2002, Nature.

[51]  B. Mpia,et al.  Combination of eflornithine and melarsoprol for melarsoprol‐resistant Gambian trypanosomiasis , 2002, Tropical medicine & international health : TM & IH.

[52]  C. Burri,et al.  Treatment of human African trypanosomiasis--present situation and needs for research and development. , 2002, The Lancet. Infectious diseases.

[53]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[54]  C. Bailly,et al.  Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin* , 2002, The Journal of Biological Chemistry.

[55]  A. Dasgupta,et al.  An insight into the active site of a type I DNA topoisomerase from the kinetoplastid protozoan Leishmania donovani. , 2002, Nucleic acids research.

[56]  Y. Mo,et al.  Nucleolar Delocalization of Human Topoisomerase I in Response to Topotecan Correlates with Sumoylation of the Protein* , 2002, The Journal of Biological Chemistry.

[57]  J. Donelson,et al.  The Genome of the African Trypanosome , 2002 .

[58]  S. Bertholet,et al.  Programmed cell death in the unicellular protozoan parasite Leishmania , 2002, Cell Death and Differentiation.

[59]  M. Roisin,et al.  Evidence for the existence of a proteasome in Toxoplasma gondii: intracellular localization and specific peptidase activities. , 2001, Parasite.

[60]  M. Wink,et al.  In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. , 2001, Planta medica.

[61]  Zefeng Wang,et al.  RNA interference of a trypanosome topoisomerase II causes progressive loss of mitochondrial DNA , 2001, The EMBO journal.

[62]  M. Bergeron,et al.  Treatment of Visceral Leishmaniasis with Sterically Stabilized Liposomes Containing Camptothecin , 2001, Antimicrobial Agents and Chemotherapy.

[63]  A. Burton.  Sharing needles may produce artificial leishmaniasis cycle. , 2001, The Lancet. Infectious diseases.

[64]  L. Liu,et al.  Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. , 2001, Cancer research.

[65]  Deborah F. Smith,et al.  Identification and characterisation of a RAD51 gene from Leishmania major. , 2001, Molecular and biochemical parasitology.

[66]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[67]  A. Dasgupta,et al.  Characterisation of the gene encoding type II DNA topoisomerase from Leishmania donovani: a key molecular target in antileishmanial therapy. , 2001, Nucleic acids research.

[68]  R. Hay,et al.  SUMO-1 Conjugation in Vivo Requires Both a Consensus Modification Motif and Nuclear Targeting* , 2001, The Journal of Biological Chemistry.

[69]  V. Nussenzweig,et al.  The ubiquitin-proteasome pathway plays an essential role in proteolysis during Trypanosoma cruzi remodeling. , 2001, Biochemistry.

[70]  Y. Pommier,et al.  Topoisomerase I-mediated DNA damage. , 2001, Advances in cancer research.

[71]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[72]  J. Champoux,et al.  Expression of Human Topoisomerase I with a Partial Deletion of the Linker Region Yields Monomeric and Dimeric Enzymes That Respond Differently to Camptothecin* , 2000, The Journal of Biological Chemistry.

[73]  S. Cheesman.  The topoisomerases of protozoan parasites. , 2000, Parasitology today.

[74]  J. Slupsky,et al.  Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. , 2000, Molecular pharmacology.

[75]  L. Liu,et al.  SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Stiles,et al.  Genomic organization, transcription, splicing and gene regulation in Leishmania. , 1999, Annals of tropical medicine and parasitology.

[77]  A. Burlingame,et al.  alpha5 subunit in Trypanosoma brucei proteasome can self-assemble to form a cylinder of four stacked heptamer rings. , 1999, The Biochemical journal.

[78]  E. Georges,et al.  Cloning and partial characterization of the proteasome S4 ATPase from Plasmodium falciparum. , 1999, Experimental parasitology.

[79]  C. Robertson.  The Leishmania mexicana proteasome. , 1999, Molecular and biochemical parasitology.

[80]  Barbara Papadopoulou,et al.  Characterization of a Leishmania donovani gene encoding a protein that closely resembles a type IB topoisomerase , 1999, Nucleic Acids Res..

[81]  H. Scholze,et al.  Isolation and subunit composition of the 20S proteasome of Giardia lamblia. , 1999, Molecular and biochemical parasitology.

[82]  I. Bruchhaus,et al.  Primary sequence of a putative non-ATPase subunit of the 26S proteasome from Entamoeba histolytica is similar to the human and yeast S2 subunit , 1999, Parasitology Research.

[83]  B. Kilbey,et al.  Plasmodium falciparum: stage-related expression of topoisomerase I. , 1999, Experimental parasitology.

[84]  J. Champoux,et al.  Structural insights into the function of type IB topoisomerases. , 1999, Current opinion in structural biology.

[85]  A. Das,et al.  Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. , 1998, Molecular pharmacology.

[86]  L. Ferguson,et al.  Mutagenic properties of topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[87]  J. Berger.  Structure of DNA topoisomerases. , 1998, Biochimica et biophysica acta.

[88]  N. Saravia,et al.  Sensitivity of Leishmania viannia panamensis to Pentavalent Antimony Is Correlated with the Formation of Cleavable DNA-Protein Complexes , 1998, Antimicrobial Agents and Chemotherapy.

[89]  R. Sternglanz,et al.  Two separate conserved domains of eukaryotic DNA topoisomerase I bind to each other and reconstitute enzymatic activity , 1998, Chromosoma.

[90]  K. Kinnamon,et al.  Activity of anticancer compounds against Trypanosoma cruzi-infected mice. , 1998, The American journal of tropical medicine and hygiene.

[91]  R. Reguera,et al.  The pharmacology of leishmaniasis. , 1998, General pharmacology.

[92]  Chonghui Cheng,et al.  Conservation of Structure and Mechanism between Eukaryotic Topoisomerase I and Site-Specific Recombinases , 1998, Cell.

[93]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[94]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[95]  A. Bodley,et al.  Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum. , 1998, Biochemical pharmacology.

[96]  J. Champoux.  Domains of human topoisomerase I and associated functions. , 1998, Progress in nucleic acid research and molecular biology.

[97]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[98]  G. Ireton,et al.  Reconstitution of human topoisomerase I by fragment complementation. , 1997, Journal of molecular biology.

[99]  A. Bodley,et al.  Topoisomerases in kinetoplastids. , 1996, Parasitology today.

[100]  G. Ireton,et al.  The Domain Organization of Human Topoisomerase I (*) , 1996, The Journal of Biological Chemistry.

[101]  B. Kilbey,et al.  The gene encoding topoisomerase I from the human malaria parasite Plasmodium falciparum. , 1995, Gene.

[102]  A. Bodley,et al.  Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. , 1995, Biochemical pharmacology.

[103]  A. Bodley,et al.  Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[104]  L. Liu,et al.  Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. , 1995, Experimental cell research.

[105]  T. Shapiro,et al.  The structure and replication of kinetoplast DNA. , 1995, Annual review of microbiology.

[106]  Christopher Lj,et al.  Identification of a type II topoisomerase gene from Cryptosporidium parvum. , 1994 .

[107]  Brian J. Kilbey,et al.  The gene encoding topoisomerase II from Plasmodium falciparum , 1994, Nucleic Acids Res..

[108]  J. Wang,et al.  DNA topoisomerases as targets of therapeutics: an overview. , 1994, Advances in pharmacology.

[109]  H. Burris,et al.  Clinical development of topoisomerase-interactive drugs. , 1994, Advances in pharmacology.

[110]  B. Gatto,et al.  DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[111]  S. Goldenberg,et al.  Cloning and characterization of the gene encoding Trypanosoma cruzi DNA topoisomerase II. , 1992, Molecular and biochemical parasitology.

[112]  J. Lovelace,et al.  Berberine derivatives as antileishmanial drugs , 1990, Antimicrobial Agents and Chemotherapy.

[113]  J. Wang,et al.  The TOP2 gene of Trypanosoma brucei: a single-copy gene that shares extensive homology with other TOP2 genes encoding eukaryotic DNA topoisomerase II. , 1990, Molecular and biochemical parasitology.

[114]  R. Docampo.  Sensitivity of parasites to free radical damage by antiparasitic drugs. , 1990, Chemico-biological interactions.

[115]  A. Chakraborty,et al.  Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. , 1988, Biochemical and biophysical research communications.

[116]  B. Hazra,et al.  Antiprotozoal activity of diospyrin towards Leishmania donovani promastigotes in vitro. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[117]  G. Riou,et al.  Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage. , 1986, Biochemistry.